AL
ALSPW.PA Spineway
- Market cap
- EUR 3.38M
- P/E
- -
- P/B
- 0.15x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- 1.8/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ALSPW.PA undervalued?
Graham numberThe Graham number of Spineway cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Spineway fundamental analysis
4 of 11 checks passedROE 0/2
The stock's ROE indicates a negative return (-4.15%) on shareholders' equity, suggesting poor financial performance.
ROA 0/2
The stock's ROA (-2.75%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.
PBV 2/2
The stock's low PBV ratio (0x) suggests it's undervalued, making it an attractive opportunity for investors.
DER 2/2
The stock has a minimal amount of debt (10%) relative to its ownership, showcasing a strong financial position and lower risk for investors.
Revenue Growth 0/2
Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.
Net Profit Growth 0/2
Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.
Assets Growth 2/2
With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.
Graham Number 1/1
The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.
Dividend Growth 0/2
The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.
Dividend 0/2
No dividends from the company in the past three years raises doubts about its profitability for shareholders.
Buffet Intrinsic Value 0/1
The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Spineway stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Spineway
Spineway SA designs, develops, and markets a range of surgical implants for spine in France. The company offers posterior fixation, including posterior osteosynthesis systems and minimal invasive posterior osteosynthesis systems; interbody fusion products, such as lumbar cage twin peaks tlif curved and oblique; motion preservation products; and biomaterials. It also exports its products. The company was incorporated in 2005 and is headquartered in Ecully, France.
Full company profileSpineway financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Spineway annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.09M | 9.59M | 6.91M | 5.59M | 3.38M | 4.29M | 7.43M | 10.5M | 12.0M | 12.4M | 22.9M |
| Gross Profit | 1.15M | 3.72M | 1.88M | 1.90M | -2.12M | -1.45M | 237K | 1.63M | 3.36M | 3.27M | 3.89M |
| Operating Income | -2.26M | -845K | -3.88M | -2.33M | -1.48M | -1.21M | -6.42M | -4.52M | -5.77M | -2.13M | -6.58M |
| EBITDA | -1.58M | -77.0K | -3.05M | -2.08M | -1.32M | -1.05M | -2.76M | -4.79M | -5.35M | -1.12M | -4.97M |
| Net Income | -2.69M | -965K | -4.12M | -2.88M | -14.0M | -1.58M | -3.14M | -6.51M | -3.86M | -2.24M | -6.16M |
| EPS | -53,800,000 | -19,300,000 | -51,550,000 | -5,135,714 | -379,703 | -9,536 | -5.48 | -817 | -0.01 | -0.06 | -0.17 |
| Balance Sheet | |||||||||||
| Total Assets | 9.45M | 9.91M | 7.43M | 12.8M | 14.7M | 25.6M | 27.7M | 26.3M | 30.4M | 29.5M | - |
| Total Liabilities | 8.15M | 8.14M | 6.49M | 6.28M | 4.73M | 4.69M | 5.69M | 7.26M | 6.17M | 6.40M | - |
| Shareholders' Equity | 1.30M | 1.77M | 945K | 6.49M | 10.0M | 20.9M | 22.0M | 19.1M | 24.2M | 23.1M | - |
| Cash & Short-term Investments | 1.45M | 2.39M | 141K | 2.58M | 4.86M | 13.9M | 5.50M | 1.80M | 4.52M | 3.50M | - |
| Total Debt | 4.32M | 5.56M | 4.23M | 4.61M | 3.09M | 3.17M | 1.43M | 2.60M | 1.82M | 1.53M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -198K | -922K | -3.41M | -1.16M | -408K | -1.80M | -1.62M | -5.83M | -3.27M | 424K | - |
| Capital Expenditure | 768K | 1.01M | 1.02M | 5.21M | 981K | 1.09M | 12.3M | 1.46M | 3.27M | 424K | 0.00 |
| Free Cash Flow | -966K | -1.93M | -4.43M | -6.37M | -1.39M | -2.88M | -13.9M | -7.29M | -3.27M | -163K | - |
| Ratios | |||||||||||
| ROE | -206.9% | -54.4% | -436.4% | -44.3% | -140.2% | -7.6% | -14.3% | -34.2% | -15.9% | -9.7% | - |
| ROA | -28.5% | -9.7% | -55.5% | -22.5% | -95.3% | -6.2% | -11.3% | -24.7% | -12.7% | -7.6% | - |
| Net Profit Margin | -52.8% | -10.1% | -59.7% | -51.5% | -415.8% | -36.9% | -42.2% | -61.9% | -32.3% | -18.0% | -26.9% |
| Debt to Equity | 3.32x | 3.14x | 4.48x | 0.71x | 0.31x | 0.15x | 0.07x | 0.14x | 0.07x | 0.07x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Spineway dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | EUR 746K | 4,494 | - |
| 2020 | EUR 2.87M | 77,541 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:2000 on Feb 27, 2024.
Who owns Spineway
Ownership data of Spineway is not available yet.
Spineway company profile
- Company name
- Spineway
- Ticker
- ALSPW.PA
- ISIN
- FR001400N2P2
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 43
- Fiscal year end
- December
- Address
- 7, allEe Moulin Berger, Ecully, France, 69130
- Phone
- 33 4 72 77 01 52
- Website
- spineway.com
About Spineway
Spineway SA designs, develops, and markets a range of surgical implants for spine in France. The company offers posterior fixation, including posterior osteosynthesis systems and minimal invasive posterior osteosynthesis systems; interbody fusion products, such as lumbar cage twin peaks tlif curved and oblique; motion preservation products; and biomaterials. It also exports its products. The company was incorporated in 2005 and is headquartered in Ecully, France.
Spineway management
9- Mr. Stephane Le RouxChairman, CEO & President
- Mr. Philippe LauritoDirector & CTO of Spineway Inc. · born 1969
- Mr. David SiegristFinancial Director
- Ms. Agnès MignaniHuman Resources Manager
- Ms. Sandrine CarleDeputy Chief Executive Officer · born 1971
- Mr. Guillaume BertetController
- Mr. Mickaël BattistiController
- Ms. Marie-Christelle DesmollesController
- Mr. Jon R. LuedkeCEO of Spineway Inc. · born 1965